In a landmark achievement for India's biotech sector and cancer treatment, Delhi-based startup Cellogen Therapeutics has received regulatory approval for the world’s first indigenous Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells. This breakthrough places India at the forefront of advanced cell and gene therapies, offering new hope for patients battling blood cancers.
India ranks third globally in cancer incidence, after the United States and China, with blood cancers accounting for 8 per cent of all newly diagnosed cases. According to the GLOBOCAN report, leukaemia, lymphoma, and multiple myeloma affect thousands of patients in India, including around 30,000 children annually.
Cellogen Therapeutics’ bi-specific CAR T platform represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T therapies that target a single antigen, this innovation engages two tumour-specific antigens simultaneously, improving treatment precision while reducing side effects such as cytokine release syndrome and neurotoxicity.
"This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine," said Dr. Gaurav Kharya, founder of Cellogen Therapeutics. “Developing this CAR T product required three years of relentless research. Our goal has always been to create world-class therapies that are both accessible and affordable, and this innovation brings us closer to that vision.”
This development aligns with the Atmanirbhar Bharat (self-reliant India) initiative, reinforcing India’s ability to drive medical innovation. CAR T therapy has traditionally been dominated by Western countries, with treatment costs exceeding USD 400,000. However, Cellogen’s technology is expected to reduce these costs by over 90 per cent, making life-saving therapies more accessible, especially in low- and middle-income countries.
Cellogen Therapeutics has received $2 million in funding from NATCO Pharma, which has acquired a 5.38 per cent stake in the company. The startup is set to begin clinical trials in collaboration with Christian Medical College (CMC), Vellore, evaluating the safety and efficacy of the therapy.
Dr. Tanveer Ahmad, lead researcher and CAR T cell therapy expert emphasised the impact of this innovation, “Our Bi-Specific 3rd Generation CAR T platform is the result of years of rigorous research and state-of-the-art cell engineering. This therapy offers a highly targeted and durable treatment option, significantly improving patient outcomes.”
The research is backed by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma.
With this approval, Cellogen Therapeutics is set to redefine cancer treatment, making CAR T therapy more effective, affordable, and accessible for Indian and global patients.
Source: Healthcare World
#healthcarestartupindia #dseidehealthcarenetwork
India ranks third globally in cancer incidence, after the United States and China, with blood cancers accounting for 8 per cent of all newly diagnosed cases. According to the GLOBOCAN report, leukaemia, lymphoma, and multiple myeloma affect thousands of patients in India, including around 30,000 children annually.
Cellogen Therapeutics’ bi-specific CAR T platform represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T therapies that target a single antigen, this innovation engages two tumour-specific antigens simultaneously, improving treatment precision while reducing side effects such as cytokine release syndrome and neurotoxicity.
"This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine," said Dr. Gaurav Kharya, founder of Cellogen Therapeutics. “Developing this CAR T product required three years of relentless research. Our goal has always been to create world-class therapies that are both accessible and affordable, and this innovation brings us closer to that vision.”
This development aligns with the Atmanirbhar Bharat (self-reliant India) initiative, reinforcing India’s ability to drive medical innovation. CAR T therapy has traditionally been dominated by Western countries, with treatment costs exceeding USD 400,000. However, Cellogen’s technology is expected to reduce these costs by over 90 per cent, making life-saving therapies more accessible, especially in low- and middle-income countries.
Cellogen Therapeutics has received $2 million in funding from NATCO Pharma, which has acquired a 5.38 per cent stake in the company. The startup is set to begin clinical trials in collaboration with Christian Medical College (CMC), Vellore, evaluating the safety and efficacy of the therapy.
Dr. Tanveer Ahmad, lead researcher and CAR T cell therapy expert emphasised the impact of this innovation, “Our Bi-Specific 3rd Generation CAR T platform is the result of years of rigorous research and state-of-the-art cell engineering. This therapy offers a highly targeted and durable treatment option, significantly improving patient outcomes.”
The research is backed by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma.
With this approval, Cellogen Therapeutics is set to redefine cancer treatment, making CAR T therapy more effective, affordable, and accessible for Indian and global patients.
Source: Healthcare World
#healthcarestartupindia #dseidehealthcarenetwork
In a landmark achievement for India's biotech sector and cancer treatment, Delhi-based startup Cellogen Therapeutics has received regulatory approval for the world’s first indigenous Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells. This breakthrough places India at the forefront of advanced cell and gene therapies, offering new hope for patients battling blood cancers.
India ranks third globally in cancer incidence, after the United States and China, with blood cancers accounting for 8 per cent of all newly diagnosed cases. According to the GLOBOCAN report, leukaemia, lymphoma, and multiple myeloma affect thousands of patients in India, including around 30,000 children annually.
Cellogen Therapeutics’ bi-specific CAR T platform represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T therapies that target a single antigen, this innovation engages two tumour-specific antigens simultaneously, improving treatment precision while reducing side effects such as cytokine release syndrome and neurotoxicity.
"This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine," said Dr. Gaurav Kharya, founder of Cellogen Therapeutics. “Developing this CAR T product required three years of relentless research. Our goal has always been to create world-class therapies that are both accessible and affordable, and this innovation brings us closer to that vision.”
This development aligns with the Atmanirbhar Bharat (self-reliant India) initiative, reinforcing India’s ability to drive medical innovation. CAR T therapy has traditionally been dominated by Western countries, with treatment costs exceeding USD 400,000. However, Cellogen’s technology is expected to reduce these costs by over 90 per cent, making life-saving therapies more accessible, especially in low- and middle-income countries.
Cellogen Therapeutics has received $2 million in funding from NATCO Pharma, which has acquired a 5.38 per cent stake in the company. The startup is set to begin clinical trials in collaboration with Christian Medical College (CMC), Vellore, evaluating the safety and efficacy of the therapy.
Dr. Tanveer Ahmad, lead researcher and CAR T cell therapy expert emphasised the impact of this innovation, “Our Bi-Specific 3rd Generation CAR T platform is the result of years of rigorous research and state-of-the-art cell engineering. This therapy offers a highly targeted and durable treatment option, significantly improving patient outcomes.”
The research is backed by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma.
With this approval, Cellogen Therapeutics is set to redefine cancer treatment, making CAR T therapy more effective, affordable, and accessible for Indian and global patients.
Source: Healthcare World
#healthcarestartupindia #dseidehealthcarenetwork
